RXRX RECURSION PHARMACEUTICALS INC

Altitude Lab Relocates to Gateway’s BioHive Hub

Altitude Lab Relocates to Gateway’s BioHive Hub

Altitude’s new facility will be housed within Recursion’s expanded headquarters and will promote increased collaboration in Downtown Salt Lake City’s rapidly growing biotech innovation ecosystem.

SALT LAKE CITY, May 25, 2023 (GLOBE NEWSWIRE) -- announced today that its incubator program and facility will leave Research Park to grow its operation in the Gateway’s BioHive hub as part of Recursion’s recently expanded headquarters. The health care incubator will join biotechs Recursion and Perfect Day in the new location in June 2023.

Launched in 2020, Altitude Lab was founded to help build a robust life sciences ecosystem in Salt Lake City by supporting early-stage startups and historically underrepresented founders. Altitude Lab, which is operated by The Recursion Foundation, has incubated 17 startups to date. These rapidly growing companies have successfully .

“In our new facility, Altitude Lab continues to reduce barriers to entrepreneurship and increase racial and gender representation in health care innovation. Vestar has been a great partner to help us get our new location up and running quickly. We are now rapidly scaling our entrepreneurial resources, lab facility, and ability to connect our community and investor network to accelerate Utah’s health care economy,” said Chandana Haque, executive director of Altitude Lab. 

The new facility will provide over 15,000 square feet of incubation space which includes shared and private labs, tissue culture facilities, over $1M in molecular and cell biology tools, and extensive site services to manage equipment and train resident scientists. In an effort to build more scientific connection, Recursion has extended use of its cafeteria to resident startups. 

“We launched Altitude Lab to help build a critical mass of biotech and health care innovation in Utah,” said Chris Gibson, Ph.D., Co-founder and CEO at Recursion. “Other leading geographies across the country, like San Francisco and Kendall Square, purposefully build spaces for scientists from many companies to congregate. Recursion is proud to be able to host more scientists in our own space to encourage this kind of collaboration and exchange of ideas. It’s an early model for the kind of supportive community we envision for Utah’s life science sector.”

Altitude Lab's new location at The Gateway’s BioHive Hub will also provide easy access to public transportation and various dining options to support social and networking events. In addition, the new space design fosters creativity and closer collaboration, focusing on providing a comfortable, modern, and centrally accessible workspace for founders.

This year, Altitude Lab graduated five companies from its program, including Teiko Bio, 3Helix, Nexeos Bio, Peel Therapeutics, and Rebel Medicine. Peel Therapeutics and Rebel Medicine plan to continue operating in private labs within Altitude’s new facility.

“Incubating at Altitude Lab helped Peel to meet scientific milestones, recruit board members, and build deeper relationships in the scientific community. Now, the private lab offering fills a much needed gap in Utah’s current real estate market. By offering additional private space to graduating companies, Altitude is enabling our biotech to scale its operation while minimizing build out costs and construction delays. We are thrilled to continue our growth alongside the Altitude community,” said Joshua Schiffman, MD, cofounder and chief executive officer of Peel Therapeutics. 

Altitude Lab is currently accepting applications. For more information about Altitude Lab visit . To register for the Fall Open House, .

About Altitude Lab

Altitude Lab is building a new, representative generation of founders to seed the next cycle of health care innovation in Utah's . Currently located in University of Utah Research Park, Altitude Lab is an incubator focused on early stage life science and health care companies. The initiative is part of a and from to foster socially-responsible entrepreneurship, job creation, and economic productivity. The Recursion Foundation, under which Altitude Lab operates, is a 501(c)(3) nonprofit organization.

Learn more at or connect on .

About Recursion

is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of , the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at , or connect on and .



Ryan Kelly
Recursion
 
EN
25/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RECURSION PHARMACEUTICALS INC

 PRESS RELEASE

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyp...

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff.Five of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82%, however, one patient showed a substantial increase from baseline.At Week 13, 50% of patients (3 out of 6) achieved ≥1-point improvement in Spigelman stage, a measure of upper GI disease severity.The early safety profile of REC-48...

 PRESS RELEASE

Recursion to Report First Quarter 2025 Business Updates and Financial ...

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 a...

 PRESS RELEASE

Recursion to Present Preliminary Clinical Data from the Ongoing Phase ...

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presen...

 PRESS RELEASE

Recursion and Enamine Release New AI-Enabled Targeted Compound Librari...

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world’s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to ac...

 PRESS RELEASE

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of R...

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinic...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch